Press Release

Sesen Bio Reports Second Quarter 2020 Financial Results and Business Update

August 10, 2020 at 7:30 AM EDT

On-track to complete BLA submission in the US in the fourth quarter of 2020

Entered into a license agreement with Qilu Pharmaceutical for the development and commercialization of Vicineum™ in Greater China with $12M upfront payment

Manufacturing of PPQ campaign drug substance batches has been completed

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 10, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported operating results for the second quarter ended June 30, 2020. The Company also provided an update on recent business development activities and the progress of manufacturing activities related to the PPQ campaign. The Company’s lead program, Vicineum, also known as VB4-845, is currently in the follow-up stage of a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (“NMIBC”). In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review.

“We are extremely pleased with the progress at Sesen Bio over the past quarter,” said Dr. Thomas Cannell, president and chief executive officer of Sesen Bio. “We signed our first licensing agreement for Vicineum outside the US with Qilu Pharmaceutical, which is a strong sign of confidence in our mission to bring this innovative therapy to more patients in need. We expect to sign additional partnerships over the next six months. Equally important, we have now completed the manufacturing of the PPQ campaign drug substance batches at Fujifilm, an important milestone in our path to completion of the BLA submission. We are currently in an exciting phase at Sesen Bio and we remain as driven as ever to bring Vicineum to market to save and improve the lives of patients with cancer.”

US and European Regulatory Update

US:

  • On June 17, 2020, Sesen received conditional acceptance of the proprietary brand name Vicineum for the Company’s product candidate, oportuzumab monatox. The Company believes Vicineum is a name with strong marketing potential that is also consistent with the FDA’s goal of preventing medication errors and potential harm to the public by ensuring that only appropriate proprietary names are approved for use. Final approval of the Vicineum brand name is conditional on FDA approval of the Company’s product candidate. The conditional acceptance of Vicineum is an important milestone in commercial readiness in the US. The Company remains on track to complete the BLA submission in the fourth quarter of 2020 and anticipates potential approval in mid-2021.

Europe:

  • Sesen Bio concluded a five-month scientific opinion process in Europe and received positive Scientific Advice for both clinical and CMC. Importantly, the Committee for Medical Products for Human Use (“CHMP”) agreed that the nonclinical and clinical pharmacology studies, and safety database are all sufficient to support a Marketing Authorization Application (“MAA”) submission for Vicineum and no additional clinical trials were requested. Additionally, the CHMP agreed that the CMC comparability plan provides a strong analytical package, and no additional clinical trials to establish comparability are deemed necessary at this time. Based on the guidance received, the Company expects to submit the MAA for Vicineum to the EMA in early 2021 with potential approval anticipated in early 2022.
  • On July 3, 2020, the Company received a product-specific pediatric waiver from the EMA for Vicineum. As part of the regulatory process for the registration of new medicines with the EMA, pharmaceutical companies are required to provide a Pediatric Investigation Plan (“PIP”) that outlines the clinical development strategy for studying the investigational product in the pediatric population. In some instances, a waiver from required pediatric studies for certain conditions may be granted by the EMA when development of a medicine for use in children is not feasible or appropriate. The PIP waiver from the EMA applies to Vicineum across all subsets of the pediatric population for the treatment of urothelial carcinoma. The receipt of the waiver will allow the Company to submit a MAA for Vicineum to the EMA without the requirement to conduct clinical studies in a pediatric population either pre-approval or post-approval.

Business Development Update

On July 30, 2020, Sesen Bio and Qilu Pharmaceutical signed a license agreement for the commercialization of Vicineum in Greater China. Under the terms of the agreement, Sesen granted Qilu Pharmaceutical a license to manufacture, develop and commercialize Vicineum for the treatment of NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan (“Greater China”). Key terms of the deal include:

  • Financial terms include significant sources of non-dilutive capital
    • Upfront payment of $12M in cash
    • Eligibility to receive up to $23M in regulatory and tech transfer milestones in addition to sales royalties for at least 12 years
  • Qilu will be the Marketing Authorization Holder and will have the exclusive rights to develop, manufacture and commercialize Vicineum in Greater China
    • Qilu will be responsible for all expenses related to these activities
    • Sesen retains full development and commercialization rights in the US and the rest of world excluding Greater China
  • Terms of the agreement include tech transfer, creating an opportunity for future CMO partnership to meet significant global demand forecasts

Manufacturing Update

Sesen Bio completed the manufacturing of the PPQ campaign drug substance batches at Fuji on schedule. Release testing is underway, and upon completion, the drug substance will be shipped to Baxter to finish the PPQ campaign for drug product, which is anticipated to be completed in September 2020. Comparability data from the PPQ campaign for drug substance and drug product are the last material deliverables before submitting the BLA in the fourth quarter of 2020.

Second Quarter 2020 Financial Results

  • Cash Position: Cash and cash equivalents were $37.7 million as of June 30, 2020, compared to $48.1 million as of December 31, 2019.
  • R&D Expenses: Research and development expenses for the second quarter of 2020 were $4.6 million compared to $7.9 million for the same period in 2019. The second quarter decrease was due primarily to timing of costs related to the ongoing technology transfer process and commercial manufacturing, in addition to lower employee compensation and lower clinical expenses related to the Phase 3 VISTA trial for Vicineum.
  • G&A Expenses: General and administrative expenses for the second quarter of 2020 were $3.3 million compared to $2.6 million for the same period in 2019. The second quarter increase was due primarily to increases in employee compensation, and legal and insurance costs, offset by slightly lower audit and professional fees.
  • Net Income (Loss): Net loss was $26.3 million, or $0.24 per basic and diluted share, for the three months ended June 30, 2020, compared to a net loss of $54.3 million, or $0.67 per basic and diluted share, for the same period in 2019. The change was primarily the result of the non-cash change in fair value of contingent consideration due to significantly higher discount rates associated with market conditions related to the COVID-19 pandemic.

About VicineumTM

Vicineum, a locally administered fusion protein, is Sesen Bio’s lead product candidate being developed for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC). Vicineum is comprised of a recombinant fusion protein that targets epithelial cell adhesion molecule (EpCAM) antigens on the surface of tumor cells to deliver a potent protein payload, Pseudomonas Exotoxin A. Vicineum is constructed with a stable, genetically engineered peptide tether to ensure the payload remains attached until it is internalized by the cancer cell, which is believed to decrease the risk of toxicity to healthy tissues, thereby improving its safety. In prior clinical trials conducted by Sesen Bio, EpCAM has been shown to be overexpressed in NMIBC cells with minimal to no EpCAM expression observed on normal bladder cells. Sesen Bio is currently conducting the Phase 3 VISTA trial, designed to support the registration of Vicineum for the treatment of high-risk NMIBC in patients who have previously received a minimum of two courses of bacillus Calmette-Guérin (BCG) and whose disease is now BCG-unresponsive. Additionally, Sesen Bio believes that cancer cell-killing properties of Vicineum promote an anti-tumor immune response that may potentially combine well with immuno-oncology drugs, such as checkpoint inhibitors. The activity of Vicineum in BCG-unresponsive NMIBC is also being explored at the US National Cancer Institute in combination with AstraZeneca’s immune checkpoint inhibitor durvalumab.

About the VISTA Clinical Trial

The VISTA trial is an open-label, multicenter, single-arm Phase 3 clinical trial evaluating the efficacy and tolerability of Vicineum™ as a monotherapy in patients with high-risk, bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). The primary endpoints of the trial are the complete response rate and the duration of response in patients with carcinoma in situ with or without papillary disease. Patients in the trial received locally administered Vicineum twice a week for six weeks, followed by once-weekly treatment for another six weeks, then treatment every other week for up to two years. To learn more about the Phase 3 VISTA trial, please visit www.clinicaltrials.gov and search the identifier NCT02449239.

About Sesen Bio

Sesen Bio, Inc. is a late-stage clinical company advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company’s lead program, Vicineum™, also known as VB4-845, is currently in a Phase 3 registration trial for the treatment of high-risk, BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In December 2019, the Company initiated the BLA submission for Vicineum to the FDA under Rolling Review. Vicineum is a locally administered targeted fusion protein composed of an anti-EpCAM antibody fragment tethered to a truncated form of Pseudomonas Exotoxin A for the treatment of high-risk NMIBC. For more information, please visit the company’s website at www.sesenbio.com.

COVID-19 Pandemic Potential Impact

Sesen Bio continues to monitor the rapidly evolving environment regarding the potential impact of the COVID-19 pandemic on our Company. The Company has not yet experienced any disruptions to our operations as a result of COVID-19, however, we are not able to quantify or predict with certainty the overall scope of potential impacts to our business, including, but not limited to, our ability to raise capital and, if approved, commercialize Vicineum. Sesen Bio remains committed to the health and safety of patients, caregivers and employees.

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: our ability to successfully develop our product candidates and complete our planned clinical programs, expectations regarding the impact of the COVID-19 pandemic, expectations regarding the timing or amounts of any payments by Qilu Pharmaceutical, expectations regarding additional partnerships for the commercialization of Vicineum outside of the US, expectations regarding the timing of completion of our BLA submission for Vicineum, expectations regarding the timing of potential approval of our BLA submission by the FDA, expectations regarding the timing of the submission of our MAA for Vicineum to the EMA, expectations regarding the timing of potential approval of our MAA submission by the EMA, expectations regarding the need for any additional clinical trials, expectations regarding the potential successful launch of Vicineum, if approved, our ability to obtain marketing approvals for our product candidates, and other factors discussed in the “Risk Factors” section of the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other reports filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

SESEN BIO, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (OPERATIONS) AND COMPREHENSIVE INCOME (LOSS)

(In thousands, except per share data)

(Unaudited)

 
 

Three Months ended

 

Six Months ended

June 30,

 

June 30,

2020

 

2019

 

2020

 

2019

Operating expenses:
Research and development

$

4,562

 

$

7,944

 

$

13,429

 

$

12,630

 

General and administrative

 

3,318

 

 

2,617

 

 

6,766

 

 

5,672

 

Change in change in fair value of contingent consideration

 

18,480

 

 

44,000

 

 

(35,220

)

 

43,000

 

Total operating expenses

 

26,360

 

 

54,561

 

 

(15,025

)

 

61,302

 

Income (Loss) from Operations

 

(26,360

)

 

(54,561

)

 

15,025

 

 

(61,302

)

Other income (expense):
Other income, net

 

16

 

 

226

 

 

195

 

 

487

 

Net Income (Loss) and Comprehensive Income (Loss)

$

(26,344

)

$

(54,335

)

$

15,220

 

$

(60,815

)

 
Net income (loss) per common share - basic

$

(0.24

)

$

(0.67

)

$

0.13

 

$

(0.77

)

Weighted-average common shares outstanding - basic

 

112,569

 

 

80,739

 

 

111,189

 

 

79,107

 

Net income (loss) per common share - diluted

$

(0.24

)

$

(0.67

)

$

0.11

 

$

(0.77

)

Weighted-average common shares outstanding - diluted

 

112,569

 

 

80,739

 

 

111,203

 

 

79,107

 

SESEN BIO, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

(Unaudited)

June 30,

December 31,

2020

2019

 
Assets
Current assets:
Cash and cash equivalents

$

37,741

 

$

48,121

 

Prepaid expense and other current assets

 

3,727

 

 

6,326

 

Total current assets

 

41,468

 

 

54,447

 

Restricted cash

 

20

 

 

20

 

Property and equipment, net

 

185

 

 

238

 

Intangibles

 

46,400

 

 

46,400

 

Goodwill

 

13,064

 

 

13,064

 

Other assets

 

76

 

 

196

 

Total Assets

$

101,213

 

$

114,365

 

Liabilities and Stockholders' Deficit
Current liabilities:
Accounts payable

$

1,274

 

$

1,902

 

Accrued expenses

 

4,866

 

 

6,169

 

Other current liabilities

 

373

 

 

446

 

Total current liabilities

 

6,513

 

 

8,517

 

Contingent consideration

 

84,800

 

 

120,020

 

Deferred tax liability

 

12,528

 

 

12,528

 

Total Liabilities

 

103,841

 

 

141,065

 

Commitments and contingencies
Stockholders' Deficit:
Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June 30,
2020 and December 31, 2019; no shares issued and outstanding at June 30, 2020 and December 31, 2019
Common stock. $0.001 par value per share; 200,000,000 shares authorized at June 30,
2020 and December 31, 2019; 116,627,653 and 106,801,409 shares issued and
outstanding at June 30, 2020 and December 31, 2019, respectively

 

116

 

 

107

 

Additional paid-in capital

 

275,560

 

 

266,717

 

Accumulated deficit

 

(278,304

)

 

(293,524

)

Total Stockholders' Deficit

 

(2,628

)

 

(26,700

)

Total Liabilities and Stockholders' Deficit

$

101,213

 

$

114,365

 

 

Erin Clark, Vice President, Corporate Strategy & Investor Relations
ir@sesenbio.com

Source: Sesen Bio, Inc.

Top